In-Vivo Evaluation of Rifampicin Loaded Nanospheres: Biodistribution and Mycobacterium Screening Studies

Order of Publishing in Issue: 
Volume :12
Issue :2
April, 2018 - June, 2018
Page No: 
Vishnu Vardhan Reddy Beeram[1], Krupanidhi S[1]*& Venkata Nadh R[2]
[1]Department of Biotechnology, Vignan’s University, Vadlamudi, Guntur-522213, India.
[2]GITAM University – Bengaluru Campus, Karnataka- 561 203, India.

Rifampicin PLGA nanospheres are formulated with a specific goal in order to decrease the dose, adverse effects and to enhance targeted drug delivery. Rifampicin nanospheres were prepared and evaluated by emulsion solvent evaporation method. In vivo bio distribution studies reveal that there was a long term accumulation of rifampicin nanospheres in the lungs over other organs. The increase in Cmax values confirmed that inhalable PLGA nanospheres are suitable for targeting and providing sustained release of antitubercular drugs to lungs. So inhalation is a selected administration route of Rifampicin PLGA nanospheres. The in vivo screening of M. tuberculosis showed good activity as well as its activity against multidrug-resistant M. tuberculosis and against M. tuberculosis isolates in a potentially latent state, makes Rifampicin PLGA nanospheres as an attractive drug dosage form for the therapy of tuberculosis. It can be concluded that there is a significant potential for effective oral delivery as well as nasal delivery of the Nanospheres for the treatment of tuberculosis.

Rifampicin Nanospheres, M. tuberculosis, In vivo Bio distribution studies.
PDF405.16 KB

To download full text articles and issues in PDF at no cost.All you have to do is fill out a brief registration form. It's easy and it's free. At any time, you may request removal of your contact information from our database.
Click here to Register | Click here if you have already registered

2018 ABAP Awards

Invitation for Nominations to 2019 ABAP Awards
The Association of Biotechnology and Pharmacy invites nominations for the following awards from the eligible talented people with proven track record and achievements on or before August 31, 2019 in the prescribed format.



User login